Quantcast

MLN0128, a mTOR inhibitor


#1

The following study suggests that MLN0128 has better antiproliferative effects than rapamycin in a synovial sarcoma cell line among others:

http://www.ncbi.nlm.nih.gov/pubmed/25519700

I remember reading about one patient with synovial sarcoma who had some success with rapamycin in combination with sutent for one year...

The future will tell if this is a good drug but for now, here are some clinical trials testing it:

https://clinicaltrials.gov/ct2/show/NCT01899053

https://clinicaltrials.gov/ct2/show/NCT02142803